Bavarian Nordic A/S (LON:0DPB)

Market Cap	1.67B +22.6%
Revenue (ttm)	695.74M -4.4%
Net Income	137.11M -11.2%
EPS	1.73 -10.7%
Shares Out	n/a
PE Ratio	12.18
Forward PE	18.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211,963
Average Volume	26,700
Open	189.70
Previous Close	198.40
Day's Range	185.70 - 194.00
52-Week Range	151.00 - 273.40
Beta	0.95
RSI	54.21
Earnings Date	May 13, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,692
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DPB

Financial Performance

In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.

Financial numbers in DKK